Our Investor Proposition

Unlocking value for our shareholders

Our growing commercial business is funding Valneva’s exciting R&D pipeline

Stock Information

€3,09 -1,28% Last update: July 19, 2019 at 17:38 CET
“We have the only clinical-stage vaccine program against Lyme disease worldwide.”
Valneva's CEO Thomas Lingelbach comments on Group Strategy

Valneva R&D Investor Day

Valneva held its R&D Investor Day on July 9, 2019 in New York.

View More

Upcoming Events

August 1, 2019

HY 2019 Financial Statements

October 28, 2019

World Vaccine Congress Europe

View Calendar

First quarter results 2019

View More

Contact

Investor Relations Team

Campus Bio-Ouest
6, Rue Alain Bombard
44800 Saint-Herblain, France
T: +33 2 28 07 37 10 investors@valneva.com

Subscribe to Valneva News

Submit

Press Releases

View More